In this episode, we explore the evolution of Astellas Pharma, from the merger of two century-old Japanese firms into a global biopharmaceutical powerhouse. We trace how a culture of disciplined research led to breakthrough medicines like Prograf, transformed transplant medicine, and later to Xtandi, a prostate cancer therapy born from academic insight and refined through global collaboration. We unpack how Astellas quietly repositioned itself toward oncology, gene therapy, and regenerative medicine while navigating the challenges of globalization, risk-taking, and long development timelines.
This episode is about how long-term thinking, scientific rigor, and cultural continuity can still win in an industry driven by speed.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#Astellas #Biotech #Pharma #DrugDiscovery #Oncology #PrecisionMedicine #JapanesePharma #Xtandi #TransplantMedicine #Biopharma #LifeSciences #PharmaStrategy #PetriDishPerspectives
© 2025 Petri Dish Perspectives LLC. All rights reserved.
